Zimmer Biomet (NYSE:ZBH) Stock Rating Lowered by Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages also recently issued reports on ZBH. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $100.00 price objective (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research note on Friday, January 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Finally, Barclays cut their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Stock Up 1.2%

ZBH stock opened at $96.32 on Friday. The stock has a fifty day moving average of $90.10 and a 200-day moving average of $95.66. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a market capitalization of $19.09 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 1.97 and a beta of 0.62. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current year.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently made changes to their positions in the company. Kestra Advisory Services LLC lifted its holdings in shares of Zimmer Biomet by 15.4% during the fourth quarter. Kestra Advisory Services LLC now owns 7,414 shares of the medical equipment provider’s stock valued at $667,000 after purchasing an additional 992 shares during the last quarter. Transamerica Financial Advisors LLC increased its position in shares of Zimmer Biomet by 45.4% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,261 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 394 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $10,394,000. The Manufacturers Life Insurance Company raised its holdings in Zimmer Biomet by 30.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 1,544,646 shares of the medical equipment provider’s stock worth $139,054,000 after acquiring an additional 360,624 shares during the last quarter. Finally, Bridgewater Associates LP lifted its position in Zimmer Biomet by 148.8% in the 4th quarter. Bridgewater Associates LP now owns 31,228 shares of the medical equipment provider’s stock valued at $2,808,000 after acquiring an additional 18,679 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.